Precision Biosciences (DTIL) EBITDA Margin (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly EBITDA Margin of 83.73% for Q1 2026, up 7616454.0% year-over-year from N/an in Q1 2025, and down 328.97% quarter-over-quarter from 36.57% in Q4 2025.
Precision Biosciences (DTIL) EBITDA Margin (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported EBITDA Margin for 9 consecutive years, with 83.73% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin rose 7616454.0% year-over-year to 83.73%; the TTM figure through Mar 2026 stood at 86.77% (down 57.0% YoY), while the FY2025 annual figure was 152.19%, down 11411.0% from the prior year.
- EBITDA Margin declined to 83.73% in Q1 2026 per DTIL's latest filing, from 36.57% in the prior quarter.
- Across five years, EBITDA Margin topped out at 48.39% in Q2 2024 and bottomed at 158976.92% in Q3 2025.
- Historically, EBITDA Margin has averaged 21574.1% across 5 years, with a median of 199.32% in 2022.
- Annual changes were most pronounced in 2025 — EBITDA Margin sank 15528335 bps — and 2026, when it soared 7616454 bps.
- Precision Biosciences' EBITDA Margin stood at 114.26% in 2022, then tumbled by 85 bps to 211.57% in 2023, then plunged by 1741 bps to 3894.36% in 2024, then jumped by 101 bps to 36.57% in 2025, then plunged by 329 bps to 83.73% in 2026.
- Business Quant data shows DTIL's EBITDA Margin at 83.73% in Q1 2026, 36.57% in Q4 2025, and 158976.92% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 19.75% |
| 10 | Precision Biosciences | 226.63 Mn | 139.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.73% |
| Dec 31, 2025 | 36.57% |
| Sep 30, 2025 | -158,976.92% |
| Jun 30, 2025 | -121,538.89% |
| Mar 31, 2025 | -76,248.28% |
| Dec 31, 2024 | -3,894.36% |
| Sep 30, 2024 | -3,693.58% |
| Jun 30, 2024 | 48.39% |
| Mar 31, 2024 | -23.81% |
| Dec 31, 2023 | -211.57% |
| Sep 30, 2023 | -94.23% |
| Jun 30, 2023 | -15.81% |
| Mar 31, 2023 | -152.10% |
| Dec 31, 2022 | -114.26% |
| Sep 30, 2022 | -199.32% |
| Jun 30, 2022 | -773.66% |
| Mar 31, 2022 | -824.09% |
| Dec 31, 2021 | -484.68% |
| Sep 30, 2021 | -48.02% |
| Jun 30, 2021 | 31.44% |